This study was designed to review clincal outcomes of Diffuse Large B Cell Lymphoma (DLBCL) treated with R-CHOP chemotherapy in the era of pegylated-filgrastim. The investigators will prospectively collect clinical data and treatment outcome of patients with DLBCL who use prophylactic pegylated-filgrastim.
* Newly diagnosed DLBCL patients treated with R-CHOP chemotherapy * Prphylactic peg-filgrastim on the day after chemotherapy
Study Type
OBSERVATIONAL
Enrollment
1,000
Ajou Universtiy School of Medicine
Suwon, Kyeonggi, South Korea
incidence of febrile neutropenia
Time frame: within 30 days
incidence of chemotherapy-related adverse events other than febrile neutropenia
Time frame: 4 weeks after completion of chemotherapy
Overall survival
Time frame: 2 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Soon Chun Yang University Hospital Bucheon
Bucheon-si, South Korea
RECRUITINGBusan Paik Hospital
Busan, South Korea
RECRUITINGChungbuk National University Hospital
Cheongju-si, South Korea
RECRUITINGKeimyung Univerisity Dongsan Medical Center
Daegu, South Korea
RECRUITINGYeungnam University Hospital
Daegu, South Korea
RECRUITINGChungnam National University Hospital
Daejeon, South Korea
RECRUITINGInje University Ilsan Paik Hospital
Ilsan, South Korea
RECRUITINGGachon University Gill Hospital
Incheon, South Korea
RECRUITINGChonbuk Nationa University Hospital
Jeonju, South Korea
RECRUITING...and 14 more locations